Evidence-Based Minireview: What is the optimal timing of anti-PD-1 antibodies in relapsed classical Hodgkin lymphoma?
| Autor: | Allen PB; Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; and., LaCasce AS; Department of Hematology and Oncology, Dana-Farber Cancer Institute, Boston, MA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2019 Dec 06; Vol. 2019 (1), pp. 249-251. |
| DOI: | 10.1182/hematology.2019000077 |
| Abstrakt: | A 26-year-old woman was initially diagnosed with stage III classical Hodgkin lymphoma (HL) treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for 6 cycles and relapsed 9 months after completing therapy. She was treated with salvage chemotherapy followed by an autologous transplantation and 1 year of brentuximab vedotin (BV) maintenance therapy. She now presents 1 year later with relapsed disease above and below the diaphragm. What treatment would you recommend for this patient? Competing Interests: Conflict-of-interest disclosure: P.B.A. and A.L. declare no competing financial interests. (© 2019 by The American Society of Hematology. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|